Table 3

Risk of pancreatic cancer associated with incretin use by time since first prescription

BelgiumLombardy RegionBelgium and Lombardy Region combined
Incretin exposure categoryPancreatic cancer (n)HR (95% CI)Pancreatic cancer (n)HR (95% CI) Pancreatic cancer (n)Summary HR (95% CI)
<3 months163.31 (1.98–5.52)143.39 (2.00–5.78)303.35 (2.32–4.84)
3 to <6 months82.34 (1.16–4.71)51.80 (0.74–4.35)132.12 (1.22–3.66)
6 to <12 months112.13 (1.17–3.88)61.66 (0.74–3.73)171.95 (1.20–3.16)
≥12 months201.74 (1.10–2.76)51.52 (0.62–3.69)251.69 (1.12–2.55)
  • HR stratified by age and sex and adjusted for gallbladder events and insulin use as time-dependent variables; the reference group is NIAD users. Summary HR was calculated by fixed-effects meta-analysis.